Helen Gogas
Helen Gogas
Verified email at med.uoa.gr
Cited by
Cited by
Nivolumab in previously untreated melanoma without BRAF mutation
C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ...
New England journal of medicine 372 (4), 320-330, 2015
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ...
New England Journal of Medicine 371 (20), 1877-1888, 2014
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ...
The Lancet 386 (9992), 444-451, 2015
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ...
New England Journal of Medicine 377 (19), 1824-1835, 2017
Prognostic significance of autoimmunity during treatment of melanoma with interferon
H Gogas, J Ioannovich, U Dafni, C Stavropoulou-Giokas, K Frangia, ...
New England Journal of Medicine 354 (7), 709-718, 2006
Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
JE Gershenwald, RA Scolyer, KR Hess, VK Sondak, GV Long, MI Ross, ...
CA: a cancer journal for clinicians 67 (6), 472-492, 2017
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
A Ribas, R Kefford, MA Marshall, CJA Punt, JB Haanen, M Marmol, ...
Journal of clinical oncology 31 (5), 616, 2013
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma
EM Van Allen, N Wagle, A Sucker, DJ Treacy, CM Johannessen, ...
Cancer discovery 4 (1), 94-109, 2014
Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study
JL Mansi, H Gogas, JM Biss, JC Gazet, U Berger, RC Coombes
The Lancet 354 (9174), 197-202, 1999
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a …
GV Long, KT Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, ...
Annals of Oncology 28 (7), 1631-1639, 2017
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
R Dummer, PA Ascierto, HJ Gogas, A Arance, M Mandala, G Liszkay, ...
The Lancet Oncology 19 (5), 603-615, 2018
Chemotherapy for metastatic melanoma: time for a change?
HJ Gogas, JM Kirkwood, VK Sondak
Cancer: Interdisciplinary International Journal of the American Cancer …, 2007
Next generation of immunotherapy for melanoma
JM Kirkwood, AA Tarhini, MC Panelli, SJ Moschos, HM Zarour, ...
Journal of Clinical Oncology 26 (20), 3445-3455, 2008
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
J Larkin, M Del Vecchio, PA Ascierto, I Krajsova, J Schachter, B Neyns, ...
The Lancet Oncology 15 (4), 436-444, 2014
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label …
R Dummer, PA Ascierto, HJ Gogas, A Arance, M Mandala, G Liszkay, ...
The Lancet Oncology 19 (10), 1315-1327, 2018
Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
DB Johnson, AM Menzies, L Zimmer, Z Eroglu, F Ye, S Zhao, H Rizos, ...
European journal of cancer 51 (18), 2792-2799, 2015
Biomarkers in melanoma
H Gogas, AMM Eggermont, A Hauschild, P Hersey, P Mohr, ...
Annals of oncology 20 (suppl_6), vi8-vi13, 2009
The treatment of brain metastases in melanoma patients
D Bafaloukos, H Gogas
Cancer treatment reviews 30 (6), 515-520, 2004
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma
C Robert, JJ Grob, D Stroyakovskiy, B Karaszewska, A Hauschild, ...
New England Journal of Medicine 381 (7), 626-636, 2019
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma
D Pectasides, U Dafni, D Bafaloukos, D Skarlos, A Polyzos, D Tsoutsos, ...
Journal of Clinical Oncology 27 (6), 939-944, 2009
The system can't perform the operation now. Try again later.
Articles 1–20